Gene Delivery in Retinal Diseases

视网膜疾病中的基因传递

• 批准号: 7034078
• 负责人: John M Nickerson
• 金额: $ 33.58万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7034078
• 关键词: DNA; birth; electrophoresis; genes; sclera

DESCRIPTION (provided by applicant): Delivery of genes and drugs to the cells of the retina is a significant challenge in the treatment of retinal and other disorders. We have developed a non-invasive method that exploits electrical fields applied trans- sclerally to efficiently deliver larger amounts of RNA or DNA to the retinal pigmented epithelium (RPE). This noninvasive approach will avoid side effects that can occur with surgical subretinal viral delivery, and repeated dosing should be easy and practical. In the future, once developed in the present simple model system, these results will guide us in adapting gene therapy to ophthalmic practice to treat diseases including glaucoma and retinal and macular degenerations. The disease and gene defect selected for this study is known to be treatable in animal models, and prior work serves as guidance and as a baseline for efficacy comparisons with our delivery approach. Our DNA delivery systems are established and meet the priority function of trans-scleral DNA delivery in vitro already. The electrical fields will be refined to aid and establish starting parameters for in vivo studies. Safety studies are planned to help achieve high delivery without damage to eye tissues or the animal. Iterative improvements are made based on optimization experiments, and outcome measures are collected both in vitro and in vivo. In the latter stages of the study, efficacy data are obtained. We plan to learn when and how to prevent severe night blindness and retinal degeneration in LCA caused by mutations in RPE65 in this project. This research project has two goals. The first goal is to optimize the amounts of nucleic acids that can be driven into the RPE trans-sclerally. The second goal is to evaluate the safety and efficacy of RPE65 gene delivery and expression in vivo in mice with lesions in this gene.

描述（由申请人提供）：将基因和药物递送至视网膜细胞是治疗视网膜和其他疾病的重大挑战。我们开发了一种非侵入性方法，利用经巩膜施加的电场，有效地将大量 RNA 或 DNA 递送至视网膜色素上皮 (RPE)。这种非侵入性方法将避免手术视网膜下病毒输送可能发生的副作用，并且重复给药应该简单实用。将来，一旦在目前的简单模型系统中得到开发，这些结果将指导我们将基因疗法应用于眼科实践，以治疗包括青光眼、视网膜和黄斑变性在内的疾病。 众所周知，本研究选择的疾病和基因缺陷在动物模型中是可以治疗的，之前的工作可以作为与我们的递送方法进行疗效比较的指导和基线。 我们的DNA递送系统已经建立并满足体外经巩膜DNA递送的优先功能。电场将被改进，以帮助和建立体内研究的起始参数。计划进行安全性研究，以帮助实现高递送率而不损害眼组织或动物。基于优化实验进行迭代改进，并收集体外和体内的结果测量。在研究的后期阶段，获得功效数据。 我们计划在这个项目中了解何时以及如何预防由 RPE65 突变引起的 LCA 严重夜盲症和视网膜变性。该研究项目有两个目标。第一个目标是优化可经巩膜进入 RPE 的核酸量。第二个目标是评估 RPE65 基因在具有该基因损伤的小鼠体内传递和表达的安全性和有效性。